Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9 Technology

Gaucher disease (GD) is caused by biallelic pathogenic variants in the acid β-glucosidase gene (GBA1), leading to a deficiency in the β-glucocerebrosidase (GCase) enzyme activity resulting in the intracellular accumulation of sphingolipids. Skeletal alterations are one of the most disabling features in GD patients. Although both defective bone formation and increased bone resorption due to osteoblast and osteoclast dysfunction contribute to GD bone pathology, the molecular bases are not fully understood, and bone disease is not completely resolved with currently available specific therapies. For this reason, using editing technology, our group has developed a reliable, isogenic, and easy-to-handle cellular model of GD monocytes (GBAKO-THP1) to facilitate GD pathophysiology studies and high-throughput drug screenings. In this work, we further characterized the model showing an increase in proinflammatory cytokines (Interleukin-1β and Tumor Necrosis Factor-α) release and activation of osteoclastogenesis. Furthermore, our data suggest that GD monocytes would display an increased osteoclastogenic potential, independent of their interaction with the GD microenvironment or other GD cells. Both proinflammatory cytokine production and osteoclastogenesis were restored at least, in part, by treating cells with the recombinant human GCase, a substrate synthase inhibitor, a pharmacological chaperone, and an anti-inflammatory compound. Besides confirming that this model would be suitable to perform high-throughput screening of therapeutic molecules that act via different mechanisms and on different phenotypic features, our data provided insights into the pathogenic cascade, leading to osteoclastogenesis exacerbation and its contribution to bone pathology in GD.

[1]  C. Mayhew,et al.  iPSC-derived neural precursor cells engineering GBA1 recovers acid β-glucosidase deficiency and diminishes α-synuclein and neuropathology. , 2023, Molecular therapy. Methods & clinical development.

[2]  M. Kumar,et al.  Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson’s disease , 2023, Human molecular genetics.

[3]  E. Borgonovi,et al.  High-cost drugs for rare diseases: their expenditure and value based on a regional area-based study , 2023, Health services management research.

[4]  D. Regier,et al.  Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone. , 2023, HealthcarePapers.

[5]  A. Rubinacci,et al.  Bone remodeling: an operational process ensuring survival and bone mechanical competence , 2022, Bone Research.

[6]  A. Pession,et al.  iPSC-Derived Gaucher Macrophages Display Growth Impairment and Activation of Inflammation-Related Cell Death , 2021, Cells.

[7]  B. Bembi,et al.  In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy , 2020, Molecular genetics and metabolism reports.

[8]  J. Delaissé,et al.  Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. , 2020, Bone.

[9]  M. Niewada,et al.  Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years , 2020, Frontiers in Pharmacology.

[10]  M. Delpino,et al.  Unraveling the mystery of Gaucher bone density pathophysiology. , 2020, Molecular genetics and metabolism.

[11]  H. Kitaura,et al.  Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption , 2020, International journal of molecular sciences.

[12]  R. Feldman,et al.  Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis. , 2020, Molecular genetics and metabolism.

[13]  H. Das,et al.  Transcriptional Regulation of Osteoclastogenesis: The Emerging Role of KLF2 , 2020, Frontiers in Immunology.

[14]  A. Dardis,et al.  CRISPR/Cas9 Editing for Gaucher Disease Modelling , 2020, International journal of molecular sciences.

[15]  Friederike Zunke,et al.  Modeling neuronopathic storage diseases with patient-derived culture systems , 2019, Neurobiology of Disease.

[16]  L. Poll,et al.  Gaucher Disease in Bone: From Pathophysiology to Practice , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  M. Ormazábal,et al.  Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease , 2019, PloS one.

[18]  A. Mehta,et al.  Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease. , 2018, Gene.

[19]  Diana Miller,et al.  Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition , 2018, Human molecular genetics.

[20]  J. Sikora,et al.  Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II , 2018, Journal of Inherited Metabolic Disease.

[21]  A. Wåhlin,et al.  Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. , 2018, Blood cells, molecules & diseases.

[22]  F. Vairo,et al.  Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1? , 2018, Blood cells, molecules & diseases.

[23]  A. Schapira,et al.  Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons , 2018, Scientific Reports.

[24]  D. Rigante,et al.  Overview of immune abnormalities in lysosomal storage disorders. , 2017, Immunology letters.

[25]  M. Plebani,et al.  Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS , 2017, Clinical chemistry and laboratory medicine.

[26]  J. Stirnemann,et al.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.

[27]  M. Delpino,et al.  Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease , 2017, International journal of molecular sciences.

[28]  F. Zito,et al.  The Alternative Faces of Macrophage Generate Osteoclasts , 2016, BioMed research international.

[29]  P. Walther,et al.  A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca²⁺ release from acidic Ca²⁺ stores. , 2015, Cell calcium.

[30]  J. Marugan,et al.  Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages , 2015, Aging cell.

[31]  M. Delpino,et al.  Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: Implication for bone pathology. , 2015, Blood cells, molecules & diseases.

[32]  R. Mignani,et al.  Early markers of Fabry disease revealed by proteomics. , 2015, Molecular bioSystems.

[33]  E. Sidransky,et al.  New macrophage models of Gaucher disease offer new tools for drug development. , 2015, Macrophage.

[34]  Ying Sun,et al.  Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology , 2015, PloS one.

[35]  Elias T. Zambidis,et al.  Gaucher iPSC‐Derived Macrophages Produce Elevated Levels of Inflammatory Mediators and Serve as a New Platform for Therapeutic Development , 2014, Stem cells.

[36]  A. Dutra,et al.  Macrophage Models of Gaucher Disease for Evaluating Disease Pathogenesis and Candidate Drugs , 2014, Science Translational Medicine.

[37]  A. Mehta,et al.  Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease. , 2013, Blood cells, molecules & diseases.

[38]  R. Faccio,et al.  The Interplay between the Bone and the Immune System , 2013, Clinical & developmental immunology.

[39]  S. Teitelbaum,et al.  Osteoclasts: New Insights , 2013, Bone Research.

[40]  I. Biton,et al.  Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. , 2012, Brain : a journal of neurology.

[41]  V. Vanneaux,et al.  Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency. , 2012, Stem cells and development.

[42]  Hongyu Zhao,et al.  Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage , 2010, Proceedings of the National Academy of Sciences.

[43]  Liza J. Raggatt,et al.  Cellular and Molecular Mechanisms of Bone Remodeling* , 2010, The Journal of Biological Chemistry.

[44]  K. Matsuo,et al.  The Mechanism of Osteoclast Differentiation Induced by IL-11 , 2009, The Journal of Immunology.

[45]  M. Itzchaki,et al.  Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy , 2004, Acta orthopaedica Scandinavica.

[46]  B. Bembi,et al.  Gaucher’s disease with Parkinson’s disease , 2003, Neurology.

[47]  J. Sussman,et al.  X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease , 2003, EMBO reports.

[48]  R. Dwek,et al.  Glucosylceramide modulates membrane traffic along the endocytic pathway Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200232-JLR200 , 2002, Journal of Lipid Research.

[49]  V. Barak,et al.  Cytokines in Gaucher's disease. , 1999, European cytokine network.

[50]  C. Hollak,et al.  Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. , 1996, Biochimica et biophysica acta.

[51]  彭明珉 Gaucher病一例 , 1995 .

[52]  Glucosylceramide modulates membrane traffic along the endocytic pathway , 2022 .